Discussions with leaders: David Mankoff talks with Jonathan Allis, a leader in the radiopharmaceutical industry, about his career and latest efforts as founding chief executive officer of Blue Earth Diagnostics . . . . . ***Page 749***

T.R.U.E. AI checklist: Buvat and Orlhac encourage consideration of 4 key questions to facilitate identification of ground-breaking and/or innovative artificial intelligence–based contributions in nuclear medicine . . . . . ***Page 752***

ARTnet collaboration: Francis and colleagues look at the successful efforts of the Australasian Radiopharmaceutical Trials Network, formed in 2014 to promote and facilitate innovative clinical research in imaging and therapy. . . . . ***Page 755***

Introduction to statistical concepts: Pugh and Torres-Saavedra provide an educational focus on basic statistical concepts—such as hypothesis testing, confidence intervals, parametric versus nonparametric tests, multiplicity, and diagnostic testing—that form the building blocks of research. . . . . ***Page 757***

PARP-1 and beyond: Puentes and colleagues review recent innovations in molecular imaging of DNA damage and repair, with an emphasis on poly[adenosine diphosphate ribose]polymerase-1 as an imaging target and predictive biomarker of response to therapy. . . . . ***Page 765***

Vaccine passports and the law: Cope and Stremitzer offer perspective on international requirements for proof of COVID-19 and their importance in achieving global herd immunity. . . . . ***Page 771***

Dynamic PSMA PET/CT and renal masses: Golan and colleagues examine the performance of dynamic ^{68}Ga-prostate-specific membrane antigen-11 PET/CT evaluation in a series of patients with newly diagnosed and localized renal masses . . . . . ***Page 773***

^{68}Ga-FAPI PET in PDAC: Röhrich and colleagues describe the clinical impact of PET/CT imaging using ^{68}Ga-labeled fibroblast activation protein inhibitors in patients with primary or progressive/recurrent pancreatic ductal carcinoma. . . . . ***Page 779***

ABT-806i against EGFR: Gan and colleagues assess the safety, biodistribution, and pharmacokinetics of ^{111}In-radiolabeled ABT-806, a tumor-specific antibody targeting the epidermal growth factor receptor, and the effects of repeated doses on receptor occupancy in patients with advanced cancers. . . . . ***Page 787***

α- versus β-therapy in multiple myeloma: Minnix and colleagues compare the potential therapeutic efficacy of β and α-emitter radioimmunotherapy using radiolabeled DOTA-daratumumab in a preclinical model of disseminated multiple myeloma. . . . . ***Page 795***

^{18}F-AraG profiling of tumors: Levi and colleagues investigate ^{18}F-arabinosyl guanine PET as a noninvasive tool that can profile tumors on the basis of CD8+ cells and evaluate the immunomodulatory effects of chemotherapy. . . . . ***Page 802***

^{18}F-FDG PET and NEN risk stratification: Binderup and colleagues assess the long-term prognostic value of ^{18}F-FDG PET imaging for risk stratification of neuroendocrine neoplasms and compare this to World Health Organization tumor grading classification. . . . . ***Page 808***

Rapid infusion in PRRT: Ebbers and colleagues document the safety of an infusion time of less than 5 min for peptide receptor radionuclide therapy with ^{177}Lu-labeled somatostatin analogs in patients with somatostatin receptor–expressing tumors . . . . . ***Page 816***

Automatic PCA tumor segmentation: Kostyszyn and colleagues detail the development of a convolutional neural network for automated contouring of intraprostatic gross tumor volume in ^{68}Ga-PSMA and ^{18}F-PSMA PET imaging. . . . . ***Page 823***

^{67}CuSarbisPSMA radionuclide therapy: McInnes and colleagues report on studies of the therapeutic potential of ^{67}Cu-CuSarbisPSMA in a prostate-specific membrane antigen–positive tumor model. . . . . ***Page 829***

Glucagon receptor PET in humans: Eriksson and colleagues describe the biodistribution and dosimetry of ^{68}Ga-Tuna-2, developed to provide a noninvasive imaging marker for the glucagon receptor, in individuals with type 2 diabetes. . . . . ***Page 833***

Optoacoustic imaging of GLP-1R: Roberts and colleagues review the development and in vivo validation of a broad-spectrum and high-absorbance near-infrared optoacoustic contrast agent, $E4_{x12}$-Cy7, for glucagonlike peptide-1 receptor imaging of small pancreatic islets in animal models. . . . . ***Page 839***

^{18}F-Flurpiridaz MPI in smaller LVs: Packard and colleagues compare the diagnostic performances of myocardial perfusion imaging with ^{99m}Tc-labeled SPECT and ^{18}F-flurpiridaz PET according to left ventricle size as part of a larger clinical trial. . . . . ***Page 849***

PET and neuropathologic staging: Blazhenets and colleagues validate imaging-based patterns of glucose metabolism and amyloid deposition related to conversion from mild cognitive impairment to Alzheimer disease against neuropathologic findings. . . . . ***Page 855***

uExplorer performance evaluation: Spencer and colleagues present a detailed physical characterization of the uExplorer total-body PET/CT system based on National Electrical Manufacturers Association NU-2-2018 and a new set of metrics characterizing total-body axial field of view. . . . . ***Page 861***

cGAN-derived PET navigators: Shiyam Sundar and colleagues describe development of a motion-correction approach aided by conditional generative adversarial network methodology to allow data-driven determination of involuntary subject motion during dynamic ^{18}F-FDG brain studies . . . . . ***Page 871***